Carnegie Mellon University
Carnegie Mellon University

ERLY Antivirals

Carnegie Mellon University
A broad-spectrum treatment for herpesviruses that withstands viral mutations and the development of drug resistance

Stage

Idea / Pre-Bootcamp

Sectors

Life Sciences

Team Members

Alex Evilevitch

Seeking

Co-Founder
Connections/Feedback
Funding

Added Info

Contact

Look for an email from AVX!
You need to Sign In to Connect! Email avx@avx.io for help
Our lab has developed novel broad-spectrum antivirals for treatment of all nine human and several animal herpesviruses that overcomes drug resistance. We have shown that the pressurized state of the viral packaged genome is a target for antiviral therapies. This pressurized DNA state in herpesvirus capsid shell (exerting tens of atmospheres of pressure) is responsible for DNA ejection into a cell nucleus, causing infection. Several lead compounds that "turn off" capsid pressure and block viral genome ejection into a cell have demonstrated superior efficacy and safety in testing conducted at the NIH/NIAID. Although high activity has been shown with all human herpesviruses and several animal herpesviruses, our focus will be on treatment of human cytomegalovirus and MDV (Marek’s disease virus in poultry). For HCMV treatment, the market is dominated by generics, such as ganciclovir and foscarne, that have low efficacy and safety profiles. For MDV, no treatments are available.

Problem & Market Focus

Resistance to all existing herpesvirus drugs occurs in immunocompromised patients where treatment is most needed. There are no antivirals to treat herpes infections in animals (many of which are fatal and highly contagious). A drug targeting the pressurized genome state in HCMV should have excellent market potential, due lack of resistance and low toxicity. For MDV a vaccine has been available since the 60’s, but vaccine breaks have occurred and there is evidence that the use of vaccine has been driving Marek´s disease herpes virus to greater virulence. We will initially target Marek´s disease in poultry as regulatory approval is faster for veterinary medicines and there is no therapeutic treatment available. The global MDV infections market is estimated to be $1 billion. The global HCMV infections market, comprising the markets of the US, the UK, France, Germany, Italy, Spain and Japan, was estimated to $246m in 2017 and will grow at a CAGR of 4.5% to reach $383m by 2027.

Technology & Value Proposition

The uniqueness of our MOA is in the absence of resistance development and broad-spectrum treatment of all herpesviruses and other viruses where pressurized viral nucleic acid state is involved in the replication (e.g. HBV, HIV, Adenoviruses, Rotaviruses). All current antiherpes drugs are nucleoside drugs targeting specific sequence on viral DNA polymerase or viral thymine kinase (TK) (e.g. acyclovir, penciclovir, ganciclovir, and foscarnet). A single amino acid mutation leads to development of drug resistance. Our work is the first to show an antiviral therapy of inhibiting viral replication by suppressing pressurized DNA ejection from the capsid into the cell nucleus, independent of nucleic acid- or protein sequence and therefore independent of the herpesvirus type (Evilevitch/CMU holds 2 approved US patents on this technology).

Keywords

Broad-spectrum, treatment, herpesviruses, viral, mutations, drug resistance, antivirals, human cytomegalovirus (HCMV), Marek’s disease virus (MDV), immunocompromised, nucleic acid, therapy, DNA pressure, veterinary, capsid
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Edit or Delete Venture

Edit
Delete
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Edit or Delete Venture

Edit
Delete